News

Tocagen and Forte Biosciences to merge.

Read time: 1 mins

Published:22nd Feb 2020

Tocagen Inc. and Forte Biosciences, Inc., a privately held clinical-stage biopharmaceutical company developing a live biotherapeutic for the treatment of inflammatory skin diseases, announced that they have entered into a definitive agreement under which Tocagen will merge with Forte in an all-stock transaction. The merged company will focus on advancing Forte's clinical program in inflammatory skin diseases, including atopic dermatitis. Upon stockholder approval, the combined company is expected to operate under the name Forte Biosciences and trade on the Nasdaq Capital Market under the ticker symbol FBRX.

Type: industry

Learning Zone

All Things Angioedema and Urticaria: Podcasts

In these podcasts, our hosts, Professor Marcus Maurer and Dr Thomas Buttgereit are joined by friends and colleagues to discuss all things related to angioedema and urticaria.

Learning Zone Homepage

Psoriasis Academy

When it comes to psoriasis, a knowledgeable healthcare professional is highly valued by patients (Pariser et al., 2016). With this in mind, we created The Psoriasis Academy, an online hub featuring succinct and easily accessible information for all healthcare professionals who want to know more about psoriasis and keep up to date with the latest developments.

Learning Zone Homepage

Improving treatment options for childhood psoriasis

This Learning Zone introduces you to our young patient Mia who, along with our paediatric psoriasis experts, helps us to describe the burden of childhood psoriasis for patients and their families, particularly the difficulties around diagnosis, comorbidities and limited treatment options.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

First presentation at AAD meeting of four-year Bimzelx (bimekizumab-bkzx) data showed long-term maintenance of complete skin clearance in moderate to severe plaque psoriasis.- UCB

UCB, a global biopharmaceutical company, announced that the first presentations of Bimzelx (bimekizumab-bkzx) four-year efficacy and safety data in the treatment of adults with moderate to severe plaque psoriasis are being shared this week at the 2024 American Academy of Dermatology (AAD) Annual Meeting in San Diego, California, U.S., March 8–12.

3 mins

Drug news

Arcutis and Sato announce strategic collaboration and licensing agreement for topical roflumilast in Japan.

Arcutis Biotherapeutics, Inc. and Sato Pharmaceutical Co., Ltd., a leading pharmaceutical company, announced that the companies have entered into a strategic collaboration and licensing agreement for the development, manufacture, and commercialization of topical roflumilast in Japan

1 min

Drug news

Japan first in the world to approve Dupixent (dupilumab) for chronic spontaneous urticaria (CSU)

Regeneron Pharmaceuticals, Inc. announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of chronic spontaneous urticaria (CSU) in people aged 12 years and older whose disease is not adequately controlled with existing therapy

1 min

See all news